LongRiver Investments

Rona Therapeutics is an RNA therapeutics platform focused on the discovery, development, and commercialization of innovative RNA medicines. The company specializes in modular and programmable RNA therapies, offering services that encompass oligonucleotide therapies, RNA editing, and polymeric molecules. Rona Therapeutics aims to create transformative RNA treatments that can significantly alter disease management across various therapeutic areas. To achieve this, the company is developing advanced facilities to enhance nucleic acid synthesis, delivery systems, oligonucleotide chemical modification, and RNA biology. By fostering an environment that promotes innovation, Rona Therapeutics is dedicated to improving patient outcomes and supporting healthier, longer lives.

Oukejian specializes in researching and developing innovative large-molecule drugs for prevalent fundus diseases.

Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline.

Zhilong New Materials is a Sino-foreign joint venture semiconductor material innovation enterprise that researches, produces, and sells semiconductor display sputtering targets and semiconductor photovoltaic targets.

Henghui Keyuan is the next generation of disruptors in the electrochemical energy storage battery business.

Rona Therapeutics is an RNA therapeutics platform focused on the discovery, development, and commercialization of innovative RNA medicines. The company specializes in modular and programmable RNA therapies, offering services that encompass oligonucleotide therapies, RNA editing, and polymeric molecules. Rona Therapeutics aims to create transformative RNA treatments that can significantly alter disease management across various therapeutic areas. To achieve this, the company is developing advanced facilities to enhance nucleic acid synthesis, delivery systems, oligonucleotide chemical modification, and RNA biology. By fostering an environment that promotes innovation, Rona Therapeutics is dedicated to improving patient outcomes and supporting healthier, longer lives.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Nanjing Tuge Healthcare Co., Ltd., established in 2018 and located in Nanjing, China, specializes in the research and development, as well as the industrialization, of advanced medical technologies. The company is particularly focused on 4K endoscopic imaging equipment and the design of digital intelligent operating rooms, aiming to enhance surgical precision and efficiency. Through its innovative approach, Tuge Medical Technology seeks to contribute significantly to the advancement of healthcare technology.

Huiyueyan Biotechnology is an innovative biomaterials firm that focuses on medical microspheres, degradable materials, and sustained-release technology.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

Ronovo Surgical is an emerging medtech company dedicated to advancing minimally invasive surgery (MIS) through innovative robotic technology. The company has developed a soft tissue surgery robot platform that utilizes next-generation robotics and advanced digital solutions to enhance surgical precision and efficiency. By focusing on various surgical specialties, Ronovo aims to optimize patient outcomes and improve health economics, particularly within the Chinese medical industry. Their efforts are designed to transform surgical care by delivering more effective and less invasive surgical options.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.